The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...
One participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous, which ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to ...
The FDA has approved Vertex Pharmaceuticals' Journavx, the first new medication to be approved in more than two decades, to ...
FDA approves new type of non-opioid pain medication in two decades - The new drug will be many times more expensive than a ...
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.